Company Overview and News

1
Brookfield Renewable Partners Offers 6.5% Starting Yield And Tremendous Growth

2018-10-10 seekingalpha
BEP is set to grow for multiple decades from the global megatrend of transferring from fossil fuel usage to renewables. It's in the early stages of growth.
BIP BEP

63
Q3 Portfolio Review

2018-10-05 seekingalpha - 1
This is the third quarter review of my retirement income portfolio. It was a very active quarter that included a final pension rollover to my IRA. About half of the rollover funds have been deployed. Some existing positions were trimmed to take profit and to diversify. In recent weeks, I've written articles about the 19 new positions, so this review will be a brief summary.
TXN CNUTF XOM RDSB ENB OPRF RDSA FTS WMT BCE CSCO ABBV DUKH BAMGF SO UPS MAIN TYT KMB CMI ENB MFC RY 0945 BNS JNJ ITW RYDBF 7203 WPC SPG ABBV MSFT QCOM PFE CLX CDUAF BAMKF NNN SOJA TM ADP SKT EPD TD ETN BNS MSCA AAPL BIP RYDAF TD CSCOI BAM BEP CU VTR IBM RDS.B RY RDS.A TNTTF APLE O DUK FDX TOYOF MSCA.CL BLK HP PEP ADPVV FTS PPL MFC

2
Brookfield Renewable Partners Is All About The Income

2018-10-04 seekingalpha
Buying low and selling high sounds like such an easy concept, but very few are able to do it well.
BAMGF BAMKF BAM BEP

2
Brookfield Renewable Partners 2018 Third Quarter Conference Call and Webcast for Investors and Analysts

2018-10-04 globenewswire
BROOKFIELD, NEWS, Oct. 04, 2018 (GLOBE NEWSWIRE) -- You are invited to participate in Brookfield Renewable Partners’ (TSX: BEP.UN; NYSE: BEP) 2018 Third Quarter Conference Call and Webcast on Wednesday October 31, 2018 at 9:00 a.m. (Eastern Time) to discuss results and current business initiatives with members of senior management.
BAMGF BAMKF BAM BEP

2
Brookfield Renewable Announces Quarterly Dividend Rate on Its Series 2 Preference Shares

2018-10-01 globenewswire
BROOKFIELD, NEWS, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Brookfield Renewable Partners L.P. (TSX: BEP.UN; NYSE: BEP) (“Brookfield Renewable”) today announced the quarterly dividend on Brookfield Renewable Power Preferred Equity Inc.’s floating-rate Class A Preference Shares, Series 2 (“Series 2 Shares”).
BAMGF BAMKF BAM BEP

1
BEP / Brookfield Renewable Partners L.P. FORM 6-K (Current Report of Foreign Issuer)

2018-10-01 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 OF THE SECURITIES EXCHA
BEP

1
BEP / Brookfield Renewable Partners L.P. FORM 20-F/A

2018-09-28 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549
BEP

3
6.4% Growing And Green Yield Is A Long-Term Dividend Growth Story

2018-09-26 seekingalpha
BEP is a revewable energy powerhouse that offers access to high-quality assets with a recession resilient business model.
BAMGF PEGI PEG GLBL BAMKF TERP BAM BEP

2
BEP / Brookfield Renewable Partners L.P. FORM 6-K (Current Report of Foreign Issuer)

2018-09-18 sec.gov - 1
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 OF THE SECURITIES EXCHA
BEP

2
Brookfield Renewable to Issue CDN$300 Million Green Bond

2018-09-18 globenewswire
BROOKFIELD, NEWS, Sept. 18, 2018 (GLOBE NEWSWIRE) -- Brookfield Renewable Partners L.P. (TSX: BEP.UN; NYSE: BEP) (“Brookfield Renewable”) today announced that it has agreed to issue CDN$300 million aggregate principal amount of medium-term notes, Series 11, due January 15, 2029, which will bear interest at a rate of 4.25% per annum, payable semi-annually (the “Notes”). The Notes will be fully and unconditionally guaranteed by Brookfield Renewable and certain of its key holding subsidiaries.
BAMGF BAMKF BAM BEP

5
11 'Safer' Utilities WallStars Show Positive Returns And Cash To Cover Dividends To September 2019

2018-09-14 seekingalpha - 2
WallStars show positive broker target price upsides. Ten top "safer" high yield dividend Utilities WallStars showed 0.84-78% net gains as of 9/11/18 broker targets plus dividends.
JE PEGI UGI HUNGF NEP TGS BKH SBS JE CZZ PEG HNP BKHU BIP 0902 BEP

2
August 2018 Portfolio Update

2018-09-04 seekingalpha
As a dividend growth investor (DGI), I am driven to keep track of both my inflows and outflows. Increases in investment income represent one measure to assess whether I am winning or losing the game of money. While I have been diligent to track my progress on a quarterly and annual basis over the past few years, through 2018, I have also been providing monthly income updates.
MTRAF WEED CGC BEP

11
Top 10 'Safer' Dividend Champions, Contenders, & Challengers Gain 18% To 35% By August 2019

2018-08-28 seekingalpha
Champion stocks sustain 25+ annual dividend-increases; Contenders show 10-24; Challengers have 5-9. WallStars show >.5% price-target upsides. 46/126 were 'safer' for showing positive annual-returns, and cash-flow yields >dividend-yields 8/24/18.
HEP PM GEO PFG HMLP GLOP PRU SUN BEP PRU PEGI PFK VLP MORN WLKP SIR PRH CVX LAZ PEG WPC PJH

1
Northview Apartment REIT: Valuation And Development Program Support Positive Outlook

2018-08-23 seekingalpha
Multi-family residential REITs are one of the best inflation hedges and one of the best hedges against rising interest rates.
CDPYF KMP.UN NVU.UN MFC 0945 NTR CCJ MFC BIP BEAV CWSRF BEP

2
3 Dividend Diamonds In The Rough

2018-08-21 seekingalpha
BEP is trading at a significant discount to NAV despite boasting an industry leading balance sheet, conservative business model, attractive yield, and strong long-term growth prospects.
ABX TERP ABX BEP

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: G16258108